Watch LEXX. Know when insiders buy.
One email the day a filing lands. Free.
LEXX
Lexaria Bioscience Corp.
4.03
+0.39 +10.71%
USD · close Nov 3
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $99.9MP/E —DIV YIELD —FCF YIELD -7.47%REV TTM $194K −68.5%NET INCOME −$7.7MNET CASH —52W 2.60 – 20.10SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · May 31 | $0 | −100.0% | — | −$2M | −$2M | — | -0.08 | −$1.6M | $0 | −$1.6M | Jul 13 |
| Q2 2026 · Feb 28 | $20K | −88.5% | 100.0% | −$1.5M | −$1.4M | — | -0.06 | −$2.2M | $41K | −$2.2M | Jul 13 |
| Q1 2026 · Nov 30 | $0 | −100.0% | — | −$1.6M | −$1.6M | — | -0.07 | −$984K | $0 | −$984K | Jul 13 |
| Q4 2025 · Aug 31derived | $174K | +107.1% | 100.0% | −$2.7M | −$2.7M | — | -0.13 | −$2.6M | $1 | −$2.6M | Nov 28 |
| Q3 2025 · May 31 | $174K | +107.1% | 100.0% | −$3.8M | −$3.8M | — | -0.21 | −$3.6M | −$1 | −$3.6M | Jul 13 |
| Q2 2025 · Feb 28 | $174K | +20.0% | 100.0% | −$2.8M | −$2.7M | — | -0.15 | −$1.5M | $1 | −$1.5M | Jul 13 |
| Q1 2025 · Nov 30 | $184K | +21.6% | 98.5% | −$2.7M | −$2.7M | — | -0.16 | −$2.7M | $25K | −$2.8M | Jul 13 |
| Q4 2024 · Aug 31derived | $84K | +173.3% | 100.0% | −$2.2M | −$2.2M | — | -0.15 | −$1.9M | $43K | −$1.9M | Nov 28 |
| Q3 2024 · May 31 | $84K | — | 100.0% | −$1.7M | −$1.8M | — | -0.13 | −$1.3M | $0 | −$1.3M | Jul 14 |
| Q2 2024 · Feb 29 | $145K | — | 100.0% | −$668K | −$650K | — | -0.06 | −$620K | $0 | −$620K | Jul 14 |
| Q1 2024 · Nov 30 | $151K | — | 96.8% | −$1.1M | −$1.2M | — | -0.13 | −$1.2M | $0 | −$1.2M | Jul 14 |
| Q4 2023 · Aug 31derived | $31K | — | 100.0% | −$1.1M | −$1.2M | — | — | −$1.6M | $0 | −$1.6M | Nov 26 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Aug 31 | $706K | 99.6% | −$11.9M | −$11.9M | -1686.0% | -0.66 | −$10.5M | $25K | −$10.5M | — | — |
| FY2024 · to Aug 31 | $464K | 99.0% | −$5.8M | −$5.8M | -1248.2% | -0.47 | −$5M | $43K | −$5M | — | — |
| FY2023 · to Aug 31 | $226K | 86.1% | −$6.5M | −$6.7M | -2946.4% | -1.01 | −$5.9M | $34K | −$5.9M | — | — |
| FY2022 · to Aug 31 | $255K | 71.9% | −$6.6M | −$7.3M | -2846.3% | — | −$4.9M | $49K | −$4.9M | — | — |
| FY2021 · to Aug 31 | $723K | 75.7% | −$5.7M | −$4M | -557.2% | -0.95 | −$4M | — | — | — | — |
| FY2020 · to Aug 31 | $315K | 68.4% | — | −$4.1M | -1297.6% | -1.47 | −$2.6M | $0 | −$2.6M | — | — |
Every number comes from Lexaria Bioscience Corp.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.